Which biotherapy to choose according to the characteristics of severe asthma in adults?

Abstract

Severe asthma remains a significant public health problem and contributes to the majority of asthma-related healthcare costs. However, for several years it has benefited from a better pathophysiological understanding and the development of biotherapies targeting various cytokines involved in airways inflammation. Currently five biolotherapies are marketed in France in this indication and a sixth should be commercialized in the course of the year2023. All the currently available biotherapies concern asthma whose inflammatory component is called type T2 (as opposed to “T2 low” asthma). The choice of a biotherapy in severe asthma must take into account the phenotype and sub-phenotype of the disease, but also the clinical characteristics of the patient, the objectives sought and the characteristics of the product. It is recommended to discuss the indication and the choice of a biotherapy within the framework of a multi-professional consultation meeting.